Potent induction therapy with interferon and ribavirin combination therapy does not achieve a higher sustained virological response rate in chronic hepatitis C with genotype 1b and high hepatitis C virus RNA level

Hepatology Research

Volumn 37, Issue 9, 2007, Pages 692-700

  Enomoto, Shotaro ^a   Tamai, Hideyuki ^a   Oka, Masashi ^a   Shingaki, Naoki ^a   Shiraki, Tatsuya ^a   Takeuchi, Machiko ^a   Deguchi, Hisanobu ^a   Magari, Hirohito ^a   Inoue, Izumi ^a   Iguchi, Mikitaka ^a   Yanaoka, Kimihiko ^a   Arii, Kenji ^a   Fujishiro, Mitsuhiro ^b   Yahagi, Naohisa ^b   Yotsuyanagi, Hiroshi ^b   Ichinose, Masao ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Chronic hepatitis C; Genotype 1b; Induction therapy; Interferon 2b; Interferon ; Ribavirin

Indexed keywords

2,5 OLIGOADENYLATE SYNTHETASE; ALANINE AMINOTRANSFERASE; BETA INTERFERON; HEMOGLOBIN; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; SYNTHETASE; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG POTENCY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENDER BIAS; GENOTYPE; HEMOGLOBIN DETERMINATION; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; INTRAOCULAR HEMORRHAGE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MUTATIONAL ANALYSIS; NONHUMAN; PEMPHIGOID; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TH1 CELL; TH2 CELL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VIRUS LOAD;

EID: 34447325598     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00112.x     Document Type: Article

References (33)

1. Oka H, Kurioka N, Kim K et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990; 12: 680-7.
2. Yoshida H, Arakawa Y, Sata M et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002; 123: 483-91.
3. Hoofnagle JH, Mullen KD, Jones DB et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986; 315: 1575-8.
4. Di Bisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-10.
5. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med, 1989; 321: 1501-6.
6. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-32.
7. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med, 1998; 339: 1485-92.
8. Reichard O, Norkrans G, Fryden A et al. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351: 83-7.
9. Davis GL, Esteban-Mur R, Rustigi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1485-92.
10. Iino S, Matsushima T, Kumada H et al. Comparison of ribavirin (SCH18098) and interferon α-2b combination therapy and interferonα-2b monotherapy in chronic hepatitis C patients of genotype 1b and high viral load - a double-blind parallel study to determine dosage and administration. J Clin Ther Med 2002; 4: 565-91 (in Japanese with English abstract).
11. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-7.
12. Kasahara A, Hayashi N, Hiramatsu N et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy with chronic hepatitis C. A multicenter randomized controlled trial. Hepatology 1995; 21: 291-7.
13. Enomoto N, Sakura I, Asahina Y et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
14. Ning Q, Brown D, Parado J et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998; 160: 3487-93.
15. Jen JF, Glue P, Gupta S et al. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000; 22: 555-65.
16. Taguchi T, Nagano-Fujii M, Akutsu M et al. Hepatitis C virus NS5A protein interacts with 2′,5′-oligoadenylate synthetase and inhibits antiviral activity of IFN in an IFN sensitivity-determining region-independent manner. J Gen Virol 2004; G85: 959-69.
17. Ichida F, Tsuji T, Omata M et al. New Inuyama classification; new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun 1996; 6: 112-19.
18. Asahina Y, Izumi N, Uchihara M et al. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta. Hepatology 2001; 34: 377-84.
19. Ikeda F, Shimomura H, Miyake M et al. Early clearance of circulating hepatitis C virus enhanced by induction therapy with twice-a-day intravenous injection of IFN-beta. J Interferon Cytokine Res 2000; 20: 831-6.
20. Shiratori Y, Perelson AS, Weinberger L et al. Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta. J Hepatol 2000; 33: 313-22.
21. Yoshioka K, Yano M, Hirofuji H et al. Randomized controlled trial of twice-a day administration of natural interferon beta for chronic hepatitis C. Hepatol Res 2000; 18: 310-19.
22. Izumi N, Kumada H, Hashimoto N et al. Rapid decrease of plasma HCV RNA in early phase of twice daily administration of 3 MU doses interferon-beta in patients with genotype 1b hepatitis C interferon: A multicenter randomized study. Dig Dis Sci 2001; 46: 516-23.
23. Suzuki F, Chayama K, Tubota A et al. Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen. J Gastroenterol 2001; 36: 242-7.
24. Bjoro K, Bell H, Hellum KB et al. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study. Scand J Gastroenterol 2002; 37: 226-32.
25. Carlsson T, Weiland O, Reichard O et al. Viral kinetics and treatment response in patients with hepatitis C during induction and standard interferon therapy in combination with ribavirin. Scand J Gastroenterol 2002; 37: 1228-34.
26. Fontana RJ, Walsh J, Moyer CA et al. High-dose interferon alfa-2b and ribavirin in patients previously treated with interferon: Results of a prospective, randomized, controlled trial. J Clin Gastroenterol 2002; 34: 177-82.
27. Mizokami M, Orito E, Gibo Y et al. Genotype, serum level of hepatitis C virus RNA and liver histology as predictors of response to interferon-alpha 2a therapy in Japanese patients with chronic hepatitis C. Liver 1996; 16: 23-7.
28. Tsubota A, Chayama K, Ikeda K et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-94.
29. Mita E, Hayashi N, Hagiwara H et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 1994; 39: 977-82.
30. Cramp ME, Rossol S, Chokshi S et al. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118: 346-55.
31. Berg T, Sarrazin C, Herrmann E et al. Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37: 600-9.
32. Tsubota A, Akuta N, Suzuki F et al. Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load. Intervirology 2002; 45: 33-42.
33. Contreras AM, Hiasa Y, He W et al. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol 2002; 76: 8505-17.